Rodabe N Amaria
M.D. Anderson Cancer Center
6
6
3
N/A
0
5
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+3 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (6)
Research Network
Collaboration Network
Research Areas & Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Aung Naing, Md
M.D. Anderson Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Siqing Fu, MD, PhD
M.D. Anderson Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
John M. Kirkwood, MD
University of Pittsburgh
Shared therapeutic areas:
Worked with same sponsors:
Jun Guo, MD
Peking University Cancer Hospital & Institute
Shared therapeutic areas:
James C Yang, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Worked with same sponsors:
loic MONDOLONI
Assistance Publique Hopitaux De Marseille
Shared therapeutic areas:
Vincent Chung
City of Hope Medical Center
Shared therapeutic areas:
Worked with same sponsors:
Murad Alam, MD
Northwestern University
Shared therapeutic areas:
Steven A Rosenberg, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Worked with same sponsors:
Bilal Omer, MD
Baylor College of Medicine
Shared therapeutic areas:
Worked with same sponsors:
Publications (0)
No publications found for this investigator.
Clinical Trials (6)
Showing 6 of 6 trials
Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma
Neoadjuvant and Adjuvant Checkpoint Blockade
Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma
Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma
Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation
Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma
All 6 trials loaded